

Date: September 30, 2024

BSE Limited
P J Towers,
Dalal Street,
Mumbai – 400 001

National Stock Exchange of India Limited
Exchange Plaza, C-1, Block G,
Bandra Kurla Complex,
Bandra (E), Mumbai – 400 051

Script Code: 543904

Symbol: MANKIND

Dear Sir/ Madam,

Subject: Outcome of Fund Raising Committee Meeting held today i.e. September 30, 2024

The Fund Raising Committee of the Company at its meeting held today i.e. September 30, 2024, has *inter-alia*, considered and finalize the issuance of Non-convertible Debentures (“NCDs”) and Commercial Papers (“CP”) as per following details:

1. Upto 500,000 INR denominated, secured, rated and listed non-convertible debentures with nominal value of INR 100,000 each, aggregating to not more than INR 50,000,000,000 in 3-4 distinct series with maturities of upto 48 months; and
2. listed and rated commercial paper having face value as may be decided in accordance with applicable law, for an aggregate financing amount of not exceeding INR 50,000,000,000 (the “CP”), in one or more tranches or series.

The detailed disclosures in respect of NCDs and CP are enclosed as Annexure I and Annexure II.

The meeting of Fund Raising Committee of commenced at 11:00 am (IST) and concluded at 12:10 p.m. (IST).

You are requested to kindly take the above information on your records.

Thanking You,

Yours Faithfully,

For **Mankind Pharma Limited**

Pradeep Chugh
Company Secretary and Compliance Officer

**Annexure I**

Sr. No.	Particulars	Debentures
1.	Type of securities proposed to be issued	Rated, Listed, Secured, Transferable, Redeemable, Non-Convertible Debentures (“NCDs”)
2.	Type of issuance	Private Placement
3.	Total number of securities proposed to be issued or the total amount for which the securities will be issued	Total number of securities: 500,000 secured, rated and listed non-convertible debentures Nominal value: INR 100,000 each,
4.	Size of the issue	Total Size of the issue: upto INR 50,000,000,000
5.	Whether proposed to be listed? If yes, name of the stock exchange(s);	BSE Limited
6.	Tenure of the instrument - date of allotment and date of maturity	Tenure of Instrument: upto 48 months Date of allotment: will be informed at the time of allotment Final Date of maturity: will be informed at the time of allotment
7.	Coupon/interest offered, schedule of payment of coupon/interest and principal;	Coupon/Interest offered: To be determined later Schedule of payment of coupon/interest and principal: Semi-Annual
8.	Charge/security, if any, created over the assets	A. Exclusive charge over the designated accounts of the Company and the collection account where issue proceeds of the NCDs are parked pending payment to the Sellers for the Acquisition. B. Pari-passu charge over movable assets (excluding current assets, bank accounts and receivables), present and future, including brands of the Company and pledge over investments of the Company in its subsidiaries and group entities; C. Pari-passu mortgage over identified immovable assets of the Company; and D. Once the acquisition is completed, the NCDs will also be secured by exclusive pledge of shares and securities of Bharat Serums and Vaccines Limited to be acquired by the Company.

MANKIND PHARMA LIMITED



9	Special right/interest/privileges attached to the instrument and changes thereof;	The rights/interests/privileges of the holders of the NCDs will be set out in the final debenture trust deed (" DTD ") to be entered into between the Company and the debenture trustee, and any other related document thereto.
10	Delay in payment of interest / principal amount for a period of more than three months from the due date or default in payment of interest / principal	Not Applicable
11	Details of any letter or comments regarding payment/non-payment of interest, principal on due dates, or any other matter concerning the security and /or the assets along with its comments thereon, if any;	Not Applicable

MANKIND PHARMA LIMITED

Regd. Office : 208, Okhla Ind. Estate, Phase - 3, New Delhi-110020 • Ph. : 011-46846700, 47476600
CIN No. L74899DL1991 PLC044843 • E-mail : contact@mankindpharma.com • www.mankindpharma.com

Restricted - External

**Annexure II**

Sr. No.	Particulars	Commercial Papers
1.	Maximum Settlement amount Size	INR 50,000,000,000
2.	Whether proposed to be listed? If yes, name of the stock exchange	BSE Limited
3.	Tenure of the instrument	In multiple tranches between 3 months to 12 months
4	Date of Allotment	will be informed at the time of allotment
5	Date of Maturity	will be informed at the time of allotment
6	Coupon/Interest offered	To be determined later
7	Schedule of payment of coupon/interest and principal	Upfront at discount
8	Charge/security, if any, created over the assets	NA
9	Issued in favor of	To be determined later
10	Special rights/interest/privileges attached to the instrument and changes thereof	Not applicable
11	Delay in payment of interest/principal amount for a period of more than 3 months from the due date or default in payment of interest/principal	Not Applicable
12	Details of any letter or comments regarding payment/non-payment of interest, principal on due dates, or any other matter concerning the security and/or the assets along with its comments thereon, if any	Not Applicable

MANKIND PHARMA LIMITED